Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 7:13:1024320.
doi: 10.3389/fendo.2022.1024320. eCollection 2022.

Posttranslational modifications in pathogenesis of PCOS

Huimei Wei  1 , Peng Huo  2 , Shun Liu  3 , Hua Huang  1 , Shun Zhang  4
Affiliations
Review

Posttranslational modifications in pathogenesis of PCOS

Huimei Wei et al. Front Endocrinol (Lausanne). .

Abstract

Polycystic ovary syndrome (PCOS) is a lifelong reproductive, metabolic, and psychiatric disorder that affects 5-18% of women, which is associated with a significantly increased lifetime risk of concomitant diseases, including type 2 diabetes, psychiatric disorders, and gynecological cancers. Posttranslational modifications (PTMs) play an important role in changes in protein function and are necessary to maintain cellular viability and biological processes, thus their maladjustment can lead to disease. Growing evidence suggests the association between PCOS and posttranslational modifications. This article mainly reviews the research status of phosphorylation, methylation, acetylation, and ubiquitination, as well as their roles and molecular mechanisms in the development of PCOS. In addition, we briefly summarize research and clinical trials of PCOS therapy to advance our understanding of agents that can be used to target phosphorylated, methylated, acetylated, and ubiquitinated PTM types. It provides not only ideas for future research on the mechanism of PCOS but also ideas for PCOS treatments with therapeutic potential.

Keywords: PCOS; acetylation; methylation; phosphorylation; posttranslational modifications; ubiquitination.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram showing the composition and regulatory mechanism of PTMs in PCOS. (Created with BioRender.com).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. . Polycystic ovary syndrome. Lancet Diabetes Endocrinol (2022) 10:668–80. doi: 10.1016/S2213-8587(22)00163-2 - DOI - PubMed
    1. Joseph S, Barai RS, Bhujbalrao R, Idicula-Thomas S. PCOSKB: A KnowledgeBase on genes, diseases, ontology terms and biochemical pathways associated with PolyCystic ovary syndrome. Nucleic Acids Res (2016) 44:D1032–1035. doi: 10.1093/nar/gkv1146 - DOI - PMC - PubMed
    1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol (2018) 14:270–84. doi: 10.1038/nrendo.2018.24 - DOI - PubMed
    1. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. . Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci (2021) 22:3789. doi: 10.3390/ijms22073789 - DOI - PMC - PubMed
    1. Iervolino M, Lepore E, Forte G, Laganà AS, Buzzaccarini G, Unfer V. Natural molecules in the management of polycystic ovary syndrome (PCOS): An analytical review. Nutrients (2021) 13:1677. doi: 10.3390/nu13051677 - DOI - PMC - PubMed